Journal: Cancers

Article Title: The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas

doi: 10.3390/cancers15061647

Figure Lengend Snippet: AXL expression. ( A ) Schematic representation of AXL receptor tyrosine kinase structure. It is composed of two immunoglobulin (Ig)-like domains that characterize extracellular domains, two fibronectin type III (FNIII) domains, a transmembrane domain and a kinase domain that is intracellular. ( B ) Flow cytometry analysis of AXL expression of sarcoma cells. ( C ) Representative FACS overlays between unstained (empty) and stained (full red) sample of each cell line. ( D ) Quantification of antibody-binding capacity (ABC) assay. ( E ) AXL-relative mRNA level determined by qRT-PCR and normalized on GAPDH housekeeping. ( F ) Western blot of AXL total form reported in a collection panel of sarcoma cells. The uncropped blots are shown in .

Article Snippet: Taq-Man ® assay (Life Technologies, Carlsbad, CA, USA) was used to detect and quantify AXL (Hs01064439_m1), and GAPDH (Hs03929097_g1) was considered to normalize the recorded threshold cycle values. qRT-PCR was performed in triplicate and relative expression was obtained through the comparative cross threshold method on a ViiA7 System (Thermo Fisher Scientific, Waltham, MA, USA).

Techniques: Expressing, Flow Cytometry, Staining, Binding Assay, Quantitative RT-PCR, Western Blot